Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2024-05-14 00:00:00 ET · period of report 2024-05-13 · accession 0001562180-24-004026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-05-14 | 2024-05-13 | AKBA | Hadas Nicole R. | SVP, CLO | S - Sale | $1.26 | -12.0K | 651.2K | -2% | -$15.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-13 | S | D | 12,016 | $1.26 | 651,243 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. |